Skip to content
Agree.net – Lifestyle
Author:
Medicenna Therapeutics Corp.
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
June 26, 2026
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
June 11, 2026
Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
June 3, 2026
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
May 19, 2026
←
Previous Page
1
2